Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
Details : Asacol HD-Generic (mesalamine) is an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults.
Product Name : Asacol HD-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2025
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Acquisition
Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China
Details :
Product Name : Etiasa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 13, 2024
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Upsher-Smith Expands Generics Portfolio with Launch of Mesalamine Extended-Release Capsules, USP
Details : Mesalamine, also known as 5-aminosalicylic acid extended-release capsule is a small molecule, which is indicated for the maintenance of remission of ulcerative colitis in adults.
Product Name : Apriso-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2023
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila Receives US FDA Approval for Mesalamine ER Capsules
Details : Mesalamine Extended-Release capsules are indicated for the maintenance of remission of ulcerative colitis in adults. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2021
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Agreement
Kyowa Kirin Terminates ASACOL® deal with Zeria Pharmaceutical
Details : Kyowa Kirin will finish its commercialization activity for ASACOL on March 31, 2020, and Zeria will obtain the full rights of the commercialization activities for ASACOL from April 1, 2020.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Agreement